

Effect of the endometriomas on ovarian stimulation and pregnancy rate on assisted reproductive outcomes

Dipanshu Sur, Ratnabali Chakravorty, Amitoj Athwal, Aamir Javed

MAGS Medical & Research Center, Kolkata, West Bengal, India

Abstract

Endometriosis is a disease known to be detrimental to fertility. Women with endometriosis, and the presence of endometrioma, may require assisted reproductive technologies to achieve a pregnancy.

Aim: Our aim was to evaluate the effect of endometriosis and the presence of an endometrioma on outcomes of conventional *in vitro* fertilization/intra-cytoplasmic sperm injection (ICSI).

Materials and Methods: The study group consisted of 45 infertile women with either unilateral or bilateral ovarian endometrial cysts of less than 3 cm. The control group consisting of 50 patients with mild male factor infertility was candidate for ICSI treatment during the same time period as the study groups. Both groups were compared for number of oocytes retrieved, grades of oocytes, as well as embryo quantity and quality.

Results: Our findings showed similar follicle numbers, good embryo grades (I or II) and pregnancy rates in the compared groups. However, patients with endometriosis had higher gonadotropin consumption than the control group. The mean number of retrieved oocytes in patients with endometriosis was significantly lower than control group ($P < 0.0001$). The numbers of metaphase II (MII) oocytes were significantly lower in patients with endometriosis as compared to the control group 6.11 ± 2.92 vs. 9.32 ± 4.71 , respectively ($P = 0.0002$). In patients with unilateral endometriosis, there were significant differences in terms of fertilization rate, retrieved oocyte and MII oocyte between the normal and involved ovaries; $P < 0.5$.

Conclusion: The endometriomas group had a significantly poorer ovarian response and required significantly more ampoules of follicle-stimulating hormone per cycle. They showed poor ovarian response with lower total numbers of retrieved oocytes and lower MII oocytes during the stimulation phase; however, it does not affect the quality of embryos and pregnancy rate per patient.

Keywords: Endometrioma, endometriosis, IVF, ovarian reserve, pregnancy rate

Address for correspondence: Mr. Dipanshu Sur, MAGS Medical & Research Center, Kolkata 700091, West Bengal, India.
E-mail: dipanshu.sur@gmail.com

Access this article online

Quick Response Code:



Website:
www.fertilityscienceresearch.org

DOI:
10.4103/fsr.fsr_19_18

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Sur D, Chakravorty R, Athwal A, Javed A. Effect of the endometriomas on ovarian stimulation and pregnancy rate on assisted reproductive outcomes. *Fertil Sci Res* 2018;5:55-9.

INTRODUCTION

Endometriosis is a common cause of infertility. At present, approximately 20% to 35% of all patients undergoing *in vitro* fertilization (IVF) are diagnosed with endometriosis^[1,2] among who about 30% to 40% suffer from endometriomas.^[3,4] The impact of endometriomas on assisted reproductive technologies results is a controversial issue. A previous meta-analysis^[5] has shown reduced pregnancy rates in women with endometriomas who underwent IVF treatments when compared to patients with other infertility causes. However, other studies have not confirmed this finding.^[6-8] In addition, some studies have shown that endometriomas could adversely affect the number of oocytes retrieved,^[7,9] oocyte quality, fertilization rate,^[5,10] embryo quality and implantation rate.^[9,11,12] Kumbak *et al.*^[13] have also reported poor embryo quality in patients with endometriosis; yet, there have been no effect on pregnancy rate. Other studies also found no adverse effect of endometriomas on pregnancy success rates.^[14-16]

Due to these conflicting results, the optimum management of endometriomas in IVF/intra-cytoplasmic sperm injection (ICSI) cycles is not clear.^[14,17] Some authors believe that endometriomas should be removed before the IVF cycle^[18]; however, others have shown that excision of an endometriomas before an IVF cycle is likely to lead poor responses to ovarian stimulation and to impact fertility outcomes.^[19,20]

The focus of the present study was to evaluate the effect of endometriomas on ovarian response and IVF/ICSI outcomes when compared to patients with mild male factor infertility.

MATERIALS AND METHODS

This cohort study was performed at MAGS Medical and Research Center, West Bengal, India. We recruited a total of 95 women who were candidates for IVF/ICSI and fresh embryo transfers.

The study group consisted of 45 infertile women with either mono-lateral or bilateral ovarian endometrial cysts of less than 3 cm, based upon transvaginal sonographic diagnosis with diffuse low-level echoes without neoplastic or acute haemorrhage features. Patients had no histories of any ovarian surgeries. All ultrasound tests were performed by two expert technicians. Technicians performed transvaginal ultrasounds between days 1 and

8 of the cycle, before starting ovarian stimulation. The location and dimension of the endometriosis were recorded at this time.

Patients with endometriosis larger than 3 cm underwent endometriotic cystectomy, *via* laparoscopic surgery. These patients were not included at the study. There was no patient with cystectomies, defined as a laparoscopic surgery applied for women with small ovarian endometriosis.

The control group consisting of 50 patients with mild male factor infertility was candidate for ICSI treatment during the same time period as the study groups. Mild male factor infertility was defined as the presence of at least 1 million motile sperm after processing. All patients in both groups had indications for IVF/ICSI treatments, without any previous attempts.

Exclude the patients for both groups who were (1) previous history of any systematic disease or malignancy, (2) basal follicle-stimulating hormone (FSH) more than 15 mIU/ml, (3) history of three or more unsuccessful IVF attempts and (4) ovarian endometriosis less than 3 cm.

The study was approved by the local ethics committee. A written informed consent was obtained from all individuals before participation. All patients received the long protocol with a gonadotropin-releasing hormone (GnRH) agonist (0.25 mg/0.5 ml) for pituitary desensitization from the mid-luteal phase of the previous cycle to the day of hCG injection. We began gonadotrophin stimulation 14 days after subcutaneous GnRH agonist injection with daily dose of 150 IU of recombinant FSH. The dose was modified based on monitoring of serum oestradiol (E2) and ultrasound evaluation. When the level of serum oestradiol was >600 pg/ml and two or more leading follicles had mean diameters of >18 mm in two dimensions, 10,000 U of human chorionic gonadotropin were given. Transvaginal sonographically guided ovum retrieval was performed under general anaesthesia 34 h following human chorionic gonadotropin (hCG) administration. The number of dominant follicles on the day of hCG injection and the number of oocytes retrieved from ovaries of diseased site and normal sites was recorded. The definition of dominant follicle was a greatest diameter of >16 mm, or a mean diameter of >14 mm for all follicles. Transcervical or transfallopian embryo transfer was conducted 48 to 72 h after oocyte retrieval. The luteal phase was supported by three injections of 2500 U of hCG every 3rd day, beginning 48 h after oocyte retrieval,

or progesterone supplementation, beginning the day of ovum pick up until the day of β -hCG assay. Clinical pregnancy was documented by the presence of an intrauterine gestational sac on transvaginal ultrasound 4 weeks after embryo transfer.

Metaphase II (MII) oocytes were injected using ICSI procedure. Normal fertilization was confirmed when two distinct pro-nuclei were present within 16 to 18h following oocyte injection.

In ICSI cycles, cumulus-enclosed oocytes were treated with 0.1% hyaluronidase, and the cumulus cells were mechanically removed by pipetting. Oocyte maturation stage and morphology were assessed under an inverted microscope (Nikon, Nikon Eclipse Ti2, Japan) at $\times 400$ magnifications. Oocytes were classified as MII oocyte (mature oocyte), metaphase I oocyte or prophase I oocyte. Good-quality cleaved embryos^[21] were transferred 2 to 3 days after oocyte retrieval.

The initial dose, total dose and days of gonadotropin, endometrium thickness and concentration of oestradiol and progesterone on the days of hCG injection were recorded. Numbers of retrieved eggs, rate of cleavage, numbers of embryos grades I and II obtained, scores of the transferred embryos, as well as rates of clinical pregnancy and implantation were calculated.

Main outcome measures

Our primary outcomes were clinical pregnancy rate, mean number of oocyte retrieved, fertilization rate, implantation rate, antral follicle count, total stimulating hormone dose and any rates of adverse effects such as cancellation and associated complications during the IVF/ICSI treatment.

Statistical analysis

Analysis was performed using the SPSS (version 20.0; SPSS Inc., Chicago, Illinois, USA) statistical software. Between-group differences of normally distributed continuous variables were assessed by Student’s *t* test, whereas the Mann–Whitney *U* test was used for the abnormal distributed data.

Significant differences were evaluated by the Chi-square test to compare non-continuous variables. In inter-group comparison, the paired *t* test analysis and Wilcoxon signed-rank test were applied for patients with unilateral endometriosis and for non-parametric cases, respectively. Data were expressed as mean \pm standard deviation. Statistical significance was considered when *P* < 0.05.

RESULTS

The baseline characteristics including age, duration of infertility and basic concentrations of E2 and FSH level were similar between two groups [Table 1]. The numbers of MII oocytes were significantly lower in patients with endometriosis as compared to the control group 6.11 ± 2.92 vs. 9.32 ± 4.71 , respectively (*P* = 0.0002) [Table 2].

The thickness of the endometrium, follicle numbers and good quality embryos (grade I or II) were also comparable between the two groups (*P* > 0.05). Both groups had similar implantation and pregnancy rates [Table 2]. However, patients with endometriosis had higher gonadotropin consumption as compared with the control group (35.04 ± 10.11 vs. 22.92 ± 8.32 ; *P* < 0.0001).

In patients with unilateral endometriosis, we compared outcomes between the affected ovary and healthy contralateral ovary. There were significant differences in terms of fertilization rate, retrieved oocyte and MII oocyte between the normal and involved ovaries; *P* < 0.5 [Table 3].

DISCUSSION

In the present study, the numbers of MII oocytes were significantly lower in endometriosis patients than the controls. These results were consistent with previous investigations that found a lower ovarian response to gonadotropin stimulation in patients with endometriosis.^[13,22] Al-Azemi *et al.*^[23] have reported

Table 1: Comparison of the baseline characteristics between case and control groups

Variable	Case group (n = 45)	Control group (n = 50)	P value
Age (years)	30.9 \pm 3.31	32.4 \pm 4.09	0.5170
Duration of infertility (months)	35.9 \pm 24.5	35.8 \pm 24.7	0.9843
Basal FSH level (IU/l)	6.33 \pm 1.89	5.97 \pm 2.01	0.3723
Basal E2 level (pg/ml)	42.10 \pm 4.81	40.9 \pm 6.72	0.3243
Basal LH level (IU/l)	6.01 \pm 3.81	5.79 \pm 2.82	0.7482
Progesterone (nmol/l)	1.6 \pm 1.8	1.7 \pm 2.0	0.7992

Data are expressed as mean \pm SD.

Table 2: Comparison of ICSI cycles outcomes between the case and control groups

	Case group (n = 45)	Control group (n = 50)	P value
Total number of used gonadotrophin ampoules	35.04 ± 10.11	22.92 ± 8.32	<0.0001
Endometrium thickness (mm)	10.33 ± 2.11	11.09 ± 3.29	0.189
Follicle number	13.71 ± 9.19	11.79 ± 10.11	0.3372
Total number of oocytes retrieved	5.33 ± 2.1	8.9 ± 3.4	<0.0001
MII oocytes retrieved	6.11 ± 2.92	9.32 ± 4.71	0.0002
Total formed embryos	3.1 ± 1.2	5.31 ± 1.9	<0.0001
Good-quality transferred embryos	2.9 ± 0.7	2.01 ± 1.10	<0.0001
Fertilization rate (%)	145/201 (72.13)	193/323 (59.75)	0.00398
Cancellation rate (%)	6 (13.33)	4 (8.0)	0.395
Implantation rate (%)	15/120 (12.5)	18/133 (13.53)	0.810
Clinical pregnancy rate (%)	17 (37.77)	13 (26.0)	0.218

Data are expressed as mean ± SD.

Table 3: Comparison of the clinical outcomes between the normal and involved ovaries in the patients with unilateral endometriosis

	Case group (n = 40)	Normal ovary (n = 42)	P value
Follicle number	8.18 ± 4.95	7.12 ± 5.01	0.338
Total number of oocytes retrieved	1.97 ± 0.8	2.73 ± 1.01	0.0003
MII oocytes retrieved	1.81 ± 0.62	2.59 ± 0.92	<0.0001
Fertilization rate	89/120 (74.16%)	92/133 (69.1%)	0.034
Total formed embryos grade I	0.67 ± 0.8	0.82 ± 0.92	0.434
Total formed embryos grade II	0.81 ± 1.2	0.93 ± 1.37	0.674
Total formed embryos grade III	0.37 ± 0.45	0.72 ± 1.01	0.04

Data are expressed as mean ± SD.

that endometriomas led to a decreased response to gonadotropins, as reflected by the smaller number of retrieved oocytes, which was also shown in our study. Pellicer *et al.*^[24] have demonstrated that endometriosis caused poor-quality oocytes and embryos with decreased ability for implantation. Different mechanisms such as changes in autoimmune factors, cytokines or production of growth factors, increased rate of granulosa cell apoptosis and decreased steroid levels were considered as negative factors for follicular growth and oocyte maturity in these patients.^[25,26] Some previous studies have reported poor IVF-embryo transfer outcomes with endometriosis.^[9,11,12] We could not find any negative impact of endometriomas on clinical pregnancy and implantation rates. Some researchers have also shown that the existence of endometriosis did not influence embryo implantation and have proposed that the detrimental effects were limited to the fertilization phase.^[27] In patients with unilateral endometriosis, the presence of endometriosis at the time of aspiration did not compromise our ICSI outcomes. It seems that in women with unilateral disease, the contralateral intact ovary compensated for ovarian function and fertility potential.^[14] In the present study, we did not include patients who had surgery for their endometriosis. Additional studies are required to evaluate the effect of surgery.

CONCLUSION

Despite the lower response to gonadotropins in endometriosis patients, the rates of pregnancy and

implantation rates, embryo quality and fertilization of MII oocytes were not affected by the presence of the endometriosis. It seems that endometrial receptivity in two groups was similar.

ACKNOWLEDGEMENTS

The authors gratefully thank all the couples participating in the study.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Ajossa S, Mais V, Guerriero S, Paoletti AM, Caffiero A, Murgia C, *et al.* The prevalence of endometriosis in pre-menopausal women undergoing gynecological surgery. *Clin Exp Obstet Gynecol* 1994;21:195-7.
2. Farquhar CM. Extracts from the “clinical evidence”. *Endometriosis*. *BMJ* 2000;320:1449-52.
3. Jenkins S, Olive DL, Haney AF. Endometriosis: Pathogenetic implications of the anatomic distribution. *Obstet Gynecol* 1986;67:335-8.
4. Vercellini P, Chapron C, De Giorgi O, Consonni D, Frontino G, Crosignani PG. Coagulation or excision of ovarian endometriomas? *Am J Obstet Gynecol* 2003;188:606-10.
5. Barnhart K, Dunsmoor-Su R, Coutifaris C. Effect of endometriosis on in vitro fertilization. *Fertil Steril* 2002;77:1148-55.
6. Matalliotakis IM, Cakmak H, Mahutte N, Fragouli Y, Arici A, Sakkas D. Women with advanced-stage endometriosis and previous surgery

- respond less well to gonadotropin stimulation, but have similar IVF implantation and delivery rates compared with women with tubal factor infertility. *Fertil Steril* 2007;88:1568-72.
7. Suzuki T, Izumi S, Matsubayashi H, Awaji H, Yoshikata K, Makino T. Impact of ovarian endometrioma on oocytes and pregnancy outcome in in vitro fertilization. *Fertil Steril* 2005;83:908-13.
 8. Wright VC, Chang J, Jeng G, Macaluso M. Centers for disease control and prevention (CDC). Assisted reproductive technology surveillance – United States, 2005. *MMWR Surveill Summ* 2008;57:1-23.
 9. Yanushpolsky EH, Best CL, Jackson KV, Clarke RN, Barbieri RL, Hornstein MD. Effects of endometriomas on oocyte quality, embryo quality, and pregnancy rates in in vitro fertilization cycles: A prospective, case-controlled study. *J Assist Reprod Genet* 1998;15:193-7.
 10. Garcia-Velasco JA, Arici A. Is the endometrium or oocyte/embryo affected in endometriosis? *Hum Reprod* 1999;14(Suppl 2):77-89.
 11. Azem F, Lessing JB, Geva E, Shahar A, Lerner-Geva L, Yovel I, *et al.* Patients with stages III and IV endometriosis have a poorer outcome of in vitro fertilization-embryo transfer than patients with tubal infertility. *Fertil Steril* 1999;72:1107-9.
 12. Bergendal A, Naffah S, Nagy C, Bergqvist A, Sjöblom P, Hillensjö T. Outcome of IVF in patients with endometriosis in comparison with tubal-factor infertility. *J Assist Reprod Genet* 1998;15:530-4.
 13. Kumbak B, Kahraman S, Karlikaya G, Lacin S, Guncy A. In vitro fertilization in normoresponder patients with endometriomas: Comparison with basal simple ovarian cysts. *Gynecol Obstet Invest* 2008;65:212-6.
 14. Somigliana E, Vercellini P, Viganó P, Ragni G, Crosignani PG. Should endometriomas be treated before IVF-ICSI cycles? *Hum Reprod Update* 2006;12:57-64.
 15. Almog B, Shehata F, Shezaf B, Tan SL, Tulandi T. Effects of ovarian endometrioma on the number of oocytes retrieved for in vitro fertilization. *Fertil Steril* 2011;95:525-7.
 16. Reinblatt SL, Ishai L, Shehata F, Son WY, Tulandi T, Almog B. Effects of ovarian endometrioma on embryo quality. *Fertil Steril* 2011;95:2700-2.
 17. De Hondt A, Meuleman C, Tomassetti C, Peeraer K, D’Hooghe TM. Endometriosis and assisted reproduction: The role for reproductive surgery? *Curr Opin Obstet Gynecol* 2006;18:374-9.
 18. Loo TC, Lin MY, Chen SH, Chung MT, Tang HH, Lin LY, *et al.* Endometrioma undergoing laparoscopic ovarian cystectomy: Its influence on the outcome of in vitro fertilization and embryo transfer (IVF-ET). *J Assist Reprod Genet* 2005;22:329-33.
 19. Demiroglu A, Guven S, Baykal C, Gurgan T. Effect of endometrioma cystectomy on IVF outcome: A prospective randomized study. *Reprod Biomed Online* 2006;12:639-43.
 20. Somigliana E, Ragni G, Benedetti F, Borroni R, Vegetti W, Crosignani PG. Does laparoscopic excision of endometriotic ovarian cysts significantly affect ovarian reserve? Insights from IVF cycles. *Hum Reprod* 2003;18:2450-3.
 21. Baczkowski T, Kurzawa R, Głabowski W. Methods of embryo scoring in in vitro fertilization. *Reprod Biol* 2004;4:5-22.
 22. Kuivasaari P, Hippeläinen M, Anttila M, Heinonen S. Effect of endometriosis on IVF/ICSI outcome: Stage III/IV endometriosis worsens cumulative pregnancy and live-born rates. *Hum Reprod* 2005;20:3130-5.
 23. Al-Azemi M, Bernal AL, Steele J, Gramsbergen I, Barlow D, Kennedy S. Ovarian response to repeated controlled stimulation in in-vitro fertilization cycles in patients with ovarian endometriosis. *Hum Reprod* 2000;15:72-5.
 24. Pellicer A, Albert C, Garrido N, Navarro J, Remohí J, Simón C. The pathophysiology of endometriosis-associated infertility: Follicular environment and embryo quality. *J Reprod Fertil Suppl* 2000;55:109-19.
 25. Lucena E, Cubillos J. Immune abnormalities in endometriosis compromising fertility in IVF-ET patients. *J Reprod Med* 1999;44:458-64.
 26. Pellicer A, Oliveira N, Ruiz A, Remohí J, Simón C. Exploring the mechanism of endometriosis-related infertility: An analysis of embryo development and implantation in assisted reproduction. *Hum Reprod* 1995;10(Suppl 2):91-7.
 27. Wong BC, Gillman NC, Oehninger S, Gibbons WE, Stadtmauer LA. Results of in vitro fertilization in patients with endometriomas: Is surgical removal beneficial? *Am J Obstet Gynecol* 2004;191: 597-607.